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Abstract
Background: Whereas T cell receptors (TCRs) detect peptide/major histocompatibility complexes (pMHCs) with
exquisite specificity, there are challenges regarding their expression and use as soluble detection molecules due to
molecular instability. We have investigated strategies for the production of TCR-immunoglobulin (Ig) fusion
proteins. Two different TCRs that are characteristic of a mouse model for idiotype (Id) dependent immune
regulation were engineered. They are structurally unrelated with different variable (V), diversity (D) and joining (J)
segments, but each share one V gene segment, either Va or Vb, with the well characterized murine TCR, 2C.
Results: Several TCR-Ig formats were assessed. In one, the TCR V domains were fused to Ig constant (C) regions. In
others, the complete extracellular part of the TCR was fused either to a complete Ig or an Ig Fc region. All
molecules were initially poorly secreted from eukaryotic cells, but replacement of unfavourable amino acids in the
V regions improved secretion, as did the introduction of a disulfide bridge between the TCR C domains and the
removal of an unpaired cysteine. A screening strategy for selection of mutations that stabilize the actual fusion
molecules was developed and used successfully. Molecules that included the complete heterodimeric TCR, with a
stabilizing disulfide bridge, were correctly folded as they bound TCR-specific antibodies (Abs) and detected pMHC
on cells after specific peptide loading.
Conclusions: We show that fully functional TCR-Ig fusion proteins can be made in good yields following stabilizing
engineering of TCR V and C region genes. This is important since TCR-Ig fusions will be important probes for the
presence of specific pMHCs in vitro and in vivo. In the absence of further affinity maturation, the reagents will be
very useful for the detection of kinetic stability of complexes of peptide and MHC.
Background
Whereas the use of recombinant soluble peptide-MHC
(pMHC) molecules for identification of specific T cells
has increased dramatically over the last years [1-3], the
reciprocal approach of using recombinant soluble TCRs
(that is, lacking the transmembrane and intracellular
part) for specific detection of peptide presentation and
targeting to specific pMHC on cells has proven far more
difficult.
A few pMHC specific antibodies have been described,
but are often cross-reactive [4-10]. The limitation may
be overcome by the use of combinatorial antibody tech-
nology as demonstrated for pMHC class I [11]. How-
ever, neither antibody libraries, nor the full range of
specific, recombinant pMHCs required for panning in
the selection step, are readily available.
TCRs have evolved to recognize pMHC. They are
detection molecules with exquisite specificity, and exhi-
bit, like antibodies, an enormous diversity. Soluble TCRs
also offer unique opportunities for novel, highly specific
therapeutic molecules. Different approaches have there-
fore been taken for production and testing of soluble
TCRs, most of which have been derived from estab-
lished T cell clones of known specificity [12].
Soluble TCRs have been produced as heterodimers of
a/b chains [13-15], or as two variable (V) domains
joined in single chain TCRs (scTCRs) of various formats
[16-20]. In general however, the development of such
molecules is hampered by difficulties associated with
low stability causing low expression yields, aggregation
of purified proteins and misfolding [21].* Correspondence: inger.sandlie@imbv.uio.no
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In order to increase stability, the TCR V regions have
been optimized by amino acid replacements. Such repla-
cements have been described that increase the surface
hydrophilicity of a scTCR derived from the human RFL
3.8 TCR [22], or yeast surface display [23] as well as
resistance to thermal denaturation [24] of a scTCR
derived from the murine 2C TCR.
In some cases, heterodimeric a/b TCRs have been sta-
bilized by a non-native disulfide bridge between the
constant (C) domains [25,26].
The intrinsic affinity of a TCR for its pMHC is in the
lower micromolar range [27]. While all TCRs on the
surface of a T cell are identical, only a few copies of a
particular pMHC are displayed on the surface of an
antigen presenting cell. Multimerization to increase
avidity has therefore been obtained by either indirect
capture on beads [28], direct biotinylation and binding
to streptavidin [17] or by expressing TCRs on larger
particles such as phage [29], viral capsids [19], or cells
[30-32].
TCRs have been fused to other soluble polypeptides,
amongst Igs, which have a number of advantages as
fusion partner since they are naturally secreted, stable
molecules. TCR-Ig molecules should be secreted and
acquire increased stability and binding avidity upon
dimerization, and detection of binding to target cells
should be facilitated utilizing the vast repertoire of avail-
able methods developed for detection of Ig. In that way,
one might tap into the successful strategies developed
for monoclonal antibodies, including widely used purifi-
cation methodology. In addition, the Fc region of TCR-
Ig fusion proteins may well provide the targeting TCRs
with effector functions in vivo, such as prolonged half
life and other FcRn mediated effects, as well as the abil-
ity to kill target cells by complement activation and
binding to Fc receptors.
However, early attempts to fuse TCRs to Ig domains
failed to produce secreted TCRs [33-35]. Later, soluble
TCR fusion proteins in which both TCR a- and b-
chains were fused to simple C domains [36,37] were
found to be secreted and recognized by anti-TCR Abs.
More recently, a scTCR consisting of Va-linker-Vb-Cb
was fused to the human IgG1 constant region [18].
Two TCRs have previously been fused to complete
IgG1 and used to stain pMHC on cell surfaces as well as
intracellularly after exogenous specific peptide loading
[38,39]. We found that such molecules were secreted at
very low levels, and therefore explored how select muta-
tions might increase expression. We focused on stabiliz-
ing mutations, as no reports exist as to how stabilizing
mutations in the TCR V or C domains may affect TCR-
Ig fusion molecule production and specificity. Here, we
describe the generation of a panel of TCR-Ig fusion pro-
teins based on two different TCRs (4B2A1 and 7A10B2)
that are specific for an Ig light chain CDR3 Id peptide
presented on an MHC class II molecule in a mouse
model for autoimmunity and tumour immunology
[40-42]. Three different fusion formats were
investigated.
Results
Design of TCR-Ig fusion proteins
Two different TCRs were fused to Ig, namely 4B2A1
and 7A10B2. Both recognize amino acid 91-101 from
the l2315 light chain of myeloma protein M315 pre-
sented on I-Ed MHC class II molecules [43]. The TCR-
Ig proteins were made in three different fusion formats
(Figure 1). In a first format, the TCR V regions were
fused to IgG C regions (TCRV-IgC). In two other for-
mats, both V and C TCR domains were included. Either,
the extracellular domains of the TCRs were fused to a
complete IgG (cTCR-cIg) or to the IgG hinge and Fc
region (cTCR-IgFc). Thus, the term “cTCR” refers to
the complete extracellular part of the TCR, including V
and C regions, whereas “cIg” refers to complete Ig.
The fusion proteins are secreted from HEK 293E cells
Genes encoding either TCRV-IgC or cTCR-cIg were
assembled on vectors designed for Ig production in
mammalian cells as described in Materials and Methods.
For each TCR, both a and b chains were tested for
fusion to both heavy and light Ig chains, a total of eight
constructs. To investigate fusion protein secretion, HEK
293E cells were transiently transfected with the genes,
and cell supernatants examined in ELISA specific for
the Ig portion of the fusions after two days. Low
Figure 1 TCR-Ig fusion protein formats. In TCRV-IgC molecules,
the Ig V regions are replaced by TCR V regions (A). cTCR-cIg
molecules have the complete extracellular part of a TCR, C+V
domains (cTCR) fused N terminally to a complete Ig (cIg) (B). In
cTCR-IgFc molecules, the extracellular part of the TCR is fused to an
Ig Fc region. TCR domains are filled and Ig domains are open circles
(C). Notably, both the a and the b portions were tested as fusions
to both the heavy and the light Ig chains in the TCRV-IgC (A) and
cTCR-cIg (B) versions.
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secretion levels were observed in all cases (Figure 2).
Fusion proteins based on the 4B2A1 receptor were
secreted at higher levels than those based on 7A10B2.
The fusion protein secreted at highest levels (~100 ng/
ml) was the 4B2A1-based TCRV-IgC construct with the
TCR Va domain fused to the heavy chain C region and
the TCR Vb domain fused to the light chain C region
(VaH+VbL).
Stability engineering of V regions improves secretion
To stabilize the TCR V domains and thus increase
secretion levels, amino acids were replaced by site direc-
ted in vitro mutagenesis. A large number of mutants
were generated and those that increased secretion levels
in the actual TCRV-IgC format selected. Targeted posi-
tions have been described [22-24], and the substitutions
tested were: S82R in 4B2A1 Va; G17E, H47Y, and L80S
in 4B2A1 Vb; L43P and W82R in 7A10B2 Va; as well as
Q17E in 7A10B2 Vb.
The mutations chosen have been identified in the con-
text of the 2C TCR, which contains the Vb8.2 and Va3.1
segments. While 4B2A1 shares the Vb8.2 segment,
7A10B2 shares Va3.1 with 2C. Thus, when the V(D)J
encoded complete V domain sequences are considered,
7B2A1 exhibits high homology to 2C Va (86.8% identity
and 88.6% similarity), while 4B2A1 exhibits high homol-
ogy to 2C Vb (89.5% identity and 92.1% similarity).
The mutagenesis reactions were performed such that
each gene acquired one or several alterations. All VaH
variants were tested in combination with all VbL var-
iants, and the best pair regarding secretion levels from
transiently transfected cells identified for each receptor
as described in Materials and methods. Analyses were
done on the constructs that were secreted at the highest
level in the previous section, namely TCRV-IgC with
VaH+VbL.
For 4B2A1, the highest protein production was
obtained when the wt a-chain was co-expressed with a
b-chain that had acquired three mutations, namely
G17E, H47Y, and L80S. As shown in Figure 3A, the
mutant fusion protein, denoted 4 Vmut, was secreted
thirteen times better than the wt. For 7A10B2, the
selected combination was L43P and W82R in Va
together with wt Vb. The protein is denoted 7 Vmut,
and production was increased seventeen fold (Figure
3A). Thus, amino acid replacements selected to improve
the thermodynamic properties of 2C, also improved
secretion of 4B2A1 as well as 7A10B2.
Folding was assessed in ELISA with a panel of anti-
TCR mAbs as coat (Table 1). GB113, which is specific
for 4B2A1 [44], and F23.2 [45], for which binding is
conformation dependent and specific for the Vb8.2 seg-
ment, were used for 4B2A1 [46]. 44-22-1 [47] and RR4-
7 [48], both of which recognize the Vb6 segment, were
used for 7A10B2. The two 4B2A1 specific reagents do
not recognize 7A10B2 and vice versa. In addition, both
receptors were tested for binding to an anti-Cb antibody,
H57, which does not recognize this format which lacks
Cb (TCRV-IgC). Importantly, none of the TCRV-IgC
molecules were recognized by the anti-TCR Abs (Figure
3B and 3C). Thus, even though the introduced muta-
tions increased secretion, correct folding was not
achieved. We therefore turned to other TCR fusion
formats.
Stability engineering of C regions improves folding and
secretion
Comparing the cTCR-cIg molecules (Figure 1B) for
secretion from HEK293E cells (Figure 2), both 4B2A1
derived molecule were secreted at medium levels. Mole-
cules with complete a chain fused to the light chain and
complete b chain fused to the heavy chain (aL + bH)
showed the best secretion.
The selected V region mutations were then introduced
in molecules of the cTCR-cIg format derived from both
Figure 2 Secretion of fusion proteins. The four molecules to the
left are derived from 4B2A1 (abbreviated 4), the four to the right
from 7A10B2 (abbreviated 7). The TCR Va domain was fused to the
heavy chain C region and the TCR Vb domain on the light chain C
region (VaH + VbL) or vice versa in the TCRV-IgC format. The
complete TCR a chain was fused to the complete heavy chain and
the TCR b chain fused to the light chain (aH + bL) or vice versa in
the cTCR-cIg format. TCR domains are filled, Ig domains are open
circles. Cell supernatant was tested in triplicates. Error bars: Standard
deviation (SD). One representative experiment out of three is
shown.
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4B2A1 and 7A10B2 (denoted 4 mut and 7 mut), the
molecules produced in HEK293E cells and secretion
levels measured by ELISA as above. For 4 mut (4B2A1
cTCR-cIg), secretion doubled, whereas no change was
observed for 7 mut (Figure 4A). Subsequently, the TCR
C regions were modified by the introduction of a disul-
fide bridge between the two C domains (mTRAC T48C
and mTRBC S57C) and by replacing an unpaired
cysteine in the b-chain with alanine, as previously
described [29].
This was done in wt as well as in V region mutated
molecules denoted 4wtSS, 4mutSS a.s.o. For 4wtSS, the
introduced disulfide bridge did not alter the secretion
level. However, when C region mutations were com-
bined with stabilizing V region mutations (4mutSS),
protein production was improved five-fold (Figure 4B).
For 7wtSS, secretion increased two fold. There was no
additive effect of V and C region mutations for the
7A10B2 derived molecule.
Folding was assessed in ELISA using anti-TCR Abs. Both
4 mut and 4 mutSS were well recognized by all relevant
antibodies (Figure 4C). For the corresponding 7A10B2
derived receptor (Figure 4D), the V region mutations alone
did not improve recognition. Introduction of the disulfide
bridge, however, did. The TCR Cb region specific mAb,
H57, bound both 4B2A1 and 7A10B2 derived molecules
with the same efficiency as the V region specific mAbs.
Two fusion molecules that were well recognized by
TCR-specific antibodies, namely 4 mutSS and 7 wtSS,
were secreted at 0.6 and 0.1 μg/ml, respectively (Figure
4B). Using the NS0 myeloma cell line, the production
rate was lower, and the supernatants of stably transfected
cells regularly contained approximately 1/10 the amount
of fusion protein as that of the HEK 293E supernatants
(data not shown). In comparison, IgGs can be obtained
from HEK293E cells at 10 μg/ml 2 days after transient
transfection. This prompted us to investigate whether
production of TCR-Igs could be increased in insect cells.
The fusion proteins are secreted from insect cells
Initially, we compared mammalian and insect cell produc-
tion of the TCRV-IgC format. The complete fusion genes
were transferred from pLNOH2 and pLNO to pAc--Fc,
which is designed for Ig production using baculovira and
insect cell infection. The Fc encoding gene originally in
the vector was deleted. Both 4B2A1 and 7A10B2 receptors
were tested. We found that the secretion levels doubled in
Sf9 insect cells compared to HEK 293E cells (Figure 5A).
The effect of V region mutations was less prominent, how-
ever, and again, the molecules were not recognized by
anti-TCR Abs (results not shown).
We then introduced the cTCR encoding genes
upstream of the Fc region encoded in the pAc--Fc vec-
tor. The 4B2A1 receptor, with or without V region
mutations as well as with or without C region muta-
tions, was tested, and a total of four different molecules
were included in the experiment. In all, the 4B2A1 a-
Figure 3 Effect of V region mutations on secretion and folding of TCRV-IgC molecules of the (VaH+VbL) format. Secretion of wild type
(wt) and mutant 4B2A1- and 7A10B7-derived fusion proteins (4V mut and 7V mut) after transfection of HEK 293E cells. One representative
experiment out of five is shown (A). Recognition by anti-TCR Abs (B). Wt and mutant 4B2A1 derived Ig-fusions were tested in ELISA using two
Abs that recognize the 4B2A1 receptor (GB113 and F23.2) and H57, which is C region specific. One representative experiment out of three is
shown (B and C). Wt and mutant 7A10B2 derived Ig-fusions were tested in ELISA using two Abs that recognize the 7A10B2 receptor (44-22-1
and RR4-7) and H57. All molecules were analyzed at the same concentration of 0.012 μg/ml. One representative experiment out of three is
shown (C). Cell supernatant was tested in triplicates. Error bars: SD
Table 1 TCR-specific Abs.
Ab clone Specificity T cell clone References
F23.2 Murine TRBV13-2 4B2A1 [45,46]
H57-597 Murine Cb 4B2A1 + 7A10B2 [64]
GB113 TCR 4B2A1 4B2A1 [44]
44-22-1 Murine TRBV19 7A10B2 [47,63]
RR4-7 Murine TRBV19 7A10B2 [48]
Lunde et al. BMC Biotechnology 2010, 10:61
http://www.biomedcentral.com/1472-6750/10/61
Page 4 of 12
chain was fused to the Fc region, whereas the b-chain
was not part of a fusion. In general, the secretion levels
were decreased relative to those obtained in mammalian
cells (Figure 5B). As for the corresponding proteins pro-
duced in HEK 293E cells, both V and C region muta-
tions increased anti-TCR Ab recognition, and the effects
were additive (Figure 5C). In conclusion, correctly
folded fusion molecules were obtained in insect cells
after introduction of V and C region mutations, and the
production levels were the same as that obtained in
mammalian cells 2 days after transient transfection.
The stability engineered fusion proteins bind specifically
to pMHC on cells
The molecules 4 Vmut and 7 Vwt (TCRV-IgC) as well
as 4 mutSS and 7 wtSS (cTCR-cIg) were tested for
binding to A20 cells in flow cytometry. A20 is a B cell
lymphoma line that expresses the I-Ed molecule. We
loaded the cells with synthetic l2315 peptide and found
that 4 mutSS and 7 wtSS bound (Figure 6), whereas 4
Vmut and 7 Vmut, neither of which bound anti-TCR
Abs, did not (data not shown). For both 4 mutSS and 7
wtSS, binding was clearly peptide-specific, as pMHC
was detected only after addition of peptide. The concen-
tration of fusion protein used, was 100 μg/ml for 4
mutSS and 17 μg/ml for 7 wtSS, respectively. When
reducing the concentration of 4 mutSS to 17 μg/ml, the
staining intensity was comparable to that of 7A10B2
(data not shown). Binding was also compared to that of
a recombinant isotype-matched mAb with I-E-specificity
[49]. For both TCR fusion proteins, staining intensities
were comparable to those of the mAb (Figure 6). F9
Figure 4 Effect of V and C region mutations on secretion and folding of cTCR-cIg molecules produced in HEK 293E cells. Secretion of
molecules with or without V region mutations (4 mut and 7 mut). One representative experiment out of three is shown (A). Secretion of
molecules with or without V region mutations and C regions with an introduced disulfide bridge (denoted SS and mutSS). One representative
experiment out of three is shown (B). Recognition by anti-TCR Abs. C. The 4B2A1 derived fusions were tested for binding to 4B2A1 specific
mAbs. One representative experiment out of two is shown (C and D). The 7A10B2 derived fusions were tested for binding to the 7A10B2
specific mAbs. H57 is Cb region specific. One representative experiment out of two is shown (D). Cell supernatant was tested in triplicates. Error
bars: SD
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cells are A20 transfected with l2315. We have previously
demonstrated that F9 presents the l2315 peptide on I-Ed
and induces proliferation of specific T cells [50].
We tested whether the four molecules could distin-
guish between A20 and F9. Binding was not observed to
either without addition of exogenous peptide. This
shows that the reagent requires further affinity matura-
tion to detect physiological concentrations of agonist
peptide.
Discussion
Fusion to Ig might facilitate expression, purification, as
well as recognition of soluble TCRs bound to target
pMHC. Furthermore, fusion of one TCR onto each
“arm” of the Ig molecule ensures TCR dimer formation
in the final TCR-Ig molecule, and consequently
increased pMHC binding strength due to avidity effects.
Recent advances in TCR engineering include the iden-
tification of stabilizing mutations in both V- and C
regions. We therefore investigated how such engineering
affected production and ligand binding properties of two
well characterized TCRs fused to Ig.
The best domain pairing when the TCR V regions
substitute the Ab V regions in the TCRV-IgC format,
VbCH/VaCL or VaCH/VbCL, may not easily be predicted,
since the TCR Ca domain deviates from the Ig fold and
has no clear homology with any of the Ig C domains
[51]. We found VaCH/VbCL to be secreted at the highest
level when the TCRV-IgC format was investigated for
production yield.
The TCR V regions were then optimized by amino
acid replacements introduced into this TCRV-IgC fusion
format, as shown in Figure 7A for Va and 7B for Vb.
TCR 2C and 7A10B2 share Va segment, and the two Va
replacements that were beneficiary for 7A10B2 were
Figure 5 Effect of V and C region mutations on secretion and folding of TCRV-IgC and cTCR-IgFc molecules produced in insect cells.
Secretion of 4B2A1 derived TCRV-IgC fusion proteins with or without V region mutations. One representative experiment out of three is shown
(A). Secretion of 4B2A1 derived cTCR-IgFc fusion proteins with or without V and/or C region mutations. One representative experiment out of
three is shown (B). Recognition by anti-TCR 4B2A1 specific Abs. One representative experiment out of two is shown. TCR domains are filled, and
Ig domains open circles (C). Insect cell supernatant after three rounds of amplifications was tested in triplicates. Error bars: SD.
Figure 6 Binding of TCR-Ig to specific pMHC expressing cells.
A20 cells (top panel), A20 cells loaded with synthetic peptide (A20
pept, second panel), F9 cells (third panel), and F9 cells loaded with
synthetic peptide (F9 pept, forth panel) were stained with the
4B2A1-based purified cTCR-cIg protein (4mutSS, 100 μg/ml, all left
panels) and the 7A10B2-based cTCR-cIg protein (7wtSS, 17 μg/ml, all
right panels). Thin line, PBS control; dotted line, NIP-specific Ab
(isotype matched); thick line: cTRC-cIg fusion protein; broken line, I-
E-specific Ab (isotype-matched). In each case, 106 cells were stained
after pulsing twice with 50 μM peptide, both 18 and 2 hours before
the experiment was carried out. One representative experiment out
of three is shown.
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first characterized in the context of a scTCR version of
the 2C TCR. For 4B2A1Va, the wt sequence was
selected, which already contains one of these.
4B2A1 and 2C share Vb segment, and all three Vb
replacements previously selected in the context of 2C
were also selected for 4B2A1. 7A10B2 utilizes another
Vb gene segment, and again, this already contains the
beneficiary amino acids.
The effect of the V domain mutations may be studied
at the atomic level in the crystal structure of a mutated
scTCR version of the 2C TCR (2C-T7) [52] and was
recently thoroughly analyzed by Richman et al. [53]. Fig-
ure 7C shows a ribbon representation of 2C TCR with
the five mutated positions highlighted. The Vb segment
was clearly well stabilized by the mutations, while the
Va segment was not. This emphasizes the need for
further stability engineering. Such engineering by yeast
surface display has been reported for several TCRs of
both mouse and human origin [24,54]. The widely ver-
satile phage display technology could develop the engi-
neering beyond its present state by selecting for features
such as resistance to aggregation after acid or heat
exposure as described for antibodies [55,56]. Following
initial selection, pools of V domains may be transferred
from the displayed scTCR format into a TCR-Ig format
by the method described here.
Folding was analyzed employing a panel of anti-TCR
Abs with V region specificity, and the results strongly
suggested that all detected TCRs were correctly folded.
In addition, the C region specific Ab H57 bound exactly
the same molecules as the Abs with V region specificity.
Thus, correct folding of the C domain could be used as
an indicator of correct V domain folding, while erro-
neous V domain folding, when detected, was never a
local event, but also affected the C domain. Secretion
levels from producing cells were not a good indicator of
Figure 7 Structural alignment of the V domains from the 4B2A1, 7B2A1 and 2C TCRs. Alignments of the Va (A) and Vb (B) were made
with MUSCLE [67] and annotated according to Hare et al. [68]. Amino acid positions mutated are indicated by colour code according to the
source, orange[23] and green [24]), and the resulting residues are indicated at each position. 4B2A1 was originally misaligned regarding a chain
residue 82. Ribbon representation of the 2C crystal structure (PDB ID: :1TCR) with the positions of the five mutations selected in the 4Vmut and
7Vmut variants, as given by the alignments in A and B (shown as spheres). The figure was prepared using PyMol (C).
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correct folding, however. The TCRV-IgC format with
TCR V regions and antibody C regions were well
secreted, but not properly folded and this was true for
both 4B2A1 and 7A10B2. The finding is not dependent
on the nature of the eukaryotic production system, as
the same observations were made whether the molecules
were secreted from mammalian cells or from insect
cells.
Native-like fold was readily reached upon reconstitu-
tion of the TCR V-C interphase for 4B2A1. This under-
scores the importance of this interphase whenever C
domains are present in TCRs produced in eukaryotic
cells. This also presented the opportunity for introduc-
tion of a disulfide bridge linking Ca and Cb. The corre-
sponding bridge was first introduced with a positive
effect on stability of human TCRs produced in E. coli
[25]. Here we demonstrate that the bridge improved
secretion of correctly folded cTCR-cIg molecules two
(7A10B2) and five (4B2A1) fold, respectively, for murine
TCRs. The V-C domain interphase analysis by Richman
et al. [53] points to important differences in solvent
exposure of the V domains in Abs and TCRs. In the
native 2C TCR, VaW82 is burried in the V-C inter-
phase, but is exchanged with a hydrophilic residue in
the exposed scTCR version (W82R). This hydrophilic
substitution also appeared beneficial in 7Amut selected
in the TCRV-IgC format which has the V-C interphase
of an Ab. In the cTCR-cIg format, however, the selected
W82R mutation appeared counterproductive.
The fusion proteins were produced in different eukar-
yotic cells that secrete large proteins in a functional
form, with disulfide bridges and glycosylation. HEK
293E cells were then chosen for large scale production
and functional testing. The vectors used contain the
oriP sequence that supports increased protein produc-
tion in HEK 293E which express EBV nuclear antigen 1.
Given frequent changes of growth medium, HEK 293E
cells will continue to produce protein for 2 weeks [57].
During this time, the functional TCR-Ig fusion mole-
cules could be obtained at 50 μg from an initial culture
volume of 5 ml.
Specific binding to pMHC on cells was verified by
flow cytometry after addition of the specific l2315 pep-
tide. This underscores that the reagents produced are
correctly folded and retained specificity, which was the
major goal in this study. The reagents, like soluble TCR
tetramers, will be very useful for the detection of kinetic
stability of complexes of peptide and MHC [58]. Impor-
tantly, a difference in peptide:MHC stability was recently
found to be related to autoimmune disease susceptibility
[59].
B lymphoma cells that had been transfected with the
l2315 gene were not detected. We have previously found
that this particular transfectant stimulates cloned [50,60]
or TCR-transgenic versions [61] of l2315-specific T
cells. A likely explanation is that the T cell based read-
out, with aggregation of pMHCII/TCR in immunological
synapses, is rather more sensitive than binding of solu-
ble TCRs as detected in flow cytometry. In addition,
coreceptors and costimulatory molecules on T cells do
indeed contribute to the former - but not the latter -
assay. In previous in vitro experiments, we found that
soluble 4B2A1 TCRs displayed polyvalently on phage at
3-5 copies per particle bound A20 loaded with the same
specific l2315 derived peptide as that used here, but not
F9 [29]. Thus, increasing avidity beyond the dimeric Ig
was not sufficient to detect physiological concentrations
of pMHC. It is well known that the intrinsic affinity of a
TCR for its cognate pMHC is most often in the lower
micromolar range. The affinities of Fabs are also low in
the primary humoral response. Ab binding to antigen
occurs due to polymerization to pentamers (in reality 10
binding sites) in IgM in the primary response or affinity
maturation in the secondary response. In the case of
antigen presentation, the specific pMHC levels are so
low that avidity is not going to operate. Thus, affinity
maturation will be necessary to increase the sensitivity
of the soluble TCR-Ig fusions to make them useful
probes for physiological presentation of pMHC in vitro
and in vivo.
Conclusions
Manufacturing of stable recombinant Ig molecules is
well established in a number of systems, and a large
panel of reagents for detection of Ig exists. The extra-
cellular parts of TCRs on the other hand, are difficult
to produce and handle as recombinant soluble mole-
cules, due to low intrinsic stability. Recent advances in
TCR engineering include the identification of stabiliz-
ing mutations in both V- and C regions. We therefore
investigated how such engineering affected production
and ligand binding properties of two well characterized
TCRs fused to Ig. Without engineering, the molecules
were secreted at very low levels from different eukar-
yotic cells. However, improving the thermodynamic
properties by TCR V region mutagenesis and the
introduction of a disulfide bridge between the TCR C
domains greatly improved yields. Most significantly,
the engineered molecules bound specifically to pMHC
on cells. The reagents will be very useful for the detec-
tion of kinetic stability of complexes of peptide and
MHC.
Methods
Cells and antibodies
The 4B2A1 and 7A10B2 T cell clones have previously
been described [43,62]. Both recognize amino acids
91-101 from the l2 light chain of Ab produced by the
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MOPC315 plasmacytoma (l2315) when presented on the
MHC class II molecule I-Ed.
The official IMGT (http://imgt.cines.fr/) gene segment
nomenclature is used throughout. Thus, the following
TCR gene segment re-designation of the murine T cell
clones 4B2A1 [Va1, Ja19/Vb8.2, Db, Jb1.2] and 7A10B2
[Va3, Ja1/Vb6, Db, Jb1.1] is [TRAV7D-3*01, TRAJ40*01/
TRBV13-2*01, TRBD1*01, TRBJ1-2*01] and [TRAV9-
3*01, TRAJ58*01/TRBV19*01, TRBD1*01, TRBJ1-1*01],
respectively.
Sf9, A20 and HEK 293E cells were from ATCC (Mana-
ssas, VA). F9 is A20 transfected with the l2315 light chain
gene [50]. IgG-specific Abs used in ELISA where from
Sigma-Aldrich (St. Louis, MO): two anti-human IgG3
(h IgG3) mAbs (HP6047 and HP6050), the latter being
biotinylated, goat anti-hIgG Ab (I2136), as well as HRP-
conjugated goat anti-hIgG Ab (A9544). TCR-specific
mAbs were GB113 [44] (clonotype-specific for 4B2A1),
F23.2 [45,46] (recognizes TRBV13-2), 44-22-1 [47,63]
(recognizes TRBV19), RR4-7 [48] (recognizes TRBV19),
and H57 [64] (recognizes murine Cb). F23.2, H57, 44-22-
1 were kind gifts from Dr. Uwe D. Staerz (Department of
Medicine, National Jewish Medical and Research Center,
Denver, USA), Dr. Ralph T. Kubo (Cytel Corporation,
San Diego, USA), and Dr. Hans Hengartner (Institute for
Experimental Immunology, University Hospital Zurich,
Zurich, Switzerland), respectively. RR4-7 was purchased
from BD Pharmingen (San Diego, CA, USA). Abs used
for flow cytometry were recombinant anti NIP- or I-Ed
hIgG3 described earlier [49,65], and PE-conjugated goat
anti-hIgG F(ab)2 fragments from Southern Biotechnolo-
gies (Birmingham, AL).
Generation of TCR-Ig fusion constructs
Cloning of TCR V genes and fusion to the C region of
h IgG3 (TCRV-IgC in Figure 1A) has been described
previously [57] as has cloning of complete TCR ectodo-
mains (cTCR) and fusion to complete hIgG3 (cTCR-cIg
in Figure 1B) [29]. In short, TCR a- and b-chain genes
(V or V + C) were PCR amplified from 4B2A1 and
7A10B2 cDNA. PCR primers had restriction sites for
cloning of TCR genes into the pLNOH2 and pLNO
vectors [66]. The TCR V genes were introduced
upstream from the Cg3 C region in pLNOH2 and the
C C region in pLNO, whereas the complete TCRs
were cloned upstream from a complete hIgG3 heavy
chain in pLNOH2 and a complete  light chain in
pLNO. For both formats and TCRs, TCRa was fused
to either Ig heavy or light chain, as was TCRb. In the
case of the cTCR-cIg constructs, the primers were
designed to introduce a segment encoding a GS-linker
of six amino acids between the TCRs and the Ig.
For insect cell production, the pAc--Fc vector from
PROGEN Biotechnik (Heidelberg, Germany) was used.
Initially, a BamHI site between the polyhedrin promoter
and the heavy leader in the vector as well as an EcoRV
site in the 4B2A1 b-chain were removed by in vitro
mutagenesis. Primers are given in Additional file 1.
TCR-Ig genes were PCR amplified from the pLNO vec-
tors using primers tagged with restriction sites (Addi-
tional file 1) and subcloned into pAc--Fc. For the
TCRV-IgC constructs, the PCR products included
the entire TCR-Ig fusions from pLNO vectors, and the
inserts replaced the Fc region in the vector. XhoI and
BamHI sites were used for the TCRVa-Ig heavy chains
whereas SacI and EcoRV sites were used for the
TCRVb-Ig light chains. For the cTCR-IgFc fusions (Fig-
ure 1C), the TCR a chains were amplified and intro-
duced upstream from the IgG1 Fc region in the vector,
whereas the TCR b chains were not fused to any Ig
domain. The restriction sites used were XhoI and SpeI
for the a-chain and SacI and EcoRV for the b-chain. All
restriction enzymes were from New England Biolabs
(Ipswich, MA).
In vitro mutagenesis and selection of mutants
Introduction of a disulfide bridge between the murine
TCR C domains and replacement of an unpaired b-
chain cysteine, have been described previously [29]. All
other in vitro mutagenesis reactions were performed
using the QuikChange Site-Directed Mutagenesis Kit
from Stratagene (La Jolla, CA). Mutagenesis with multi-
ple sets of primers was performed using the same proto-
col as for single site mutations, except for the presence
of more than one primer set in each tube. The muta-
tions were S82R in 4B2A1 Va; G17E, H47Y, and L80S
in 4B2A1 Vb; L43P and W82R in 7A10B2 Va; and Q17E
in 7A10B2 Vb. The primers are listed in Additional file
2. The presence of multiple primer pairs reduced the
frequency of mutation at each targeted site to approxi-
mately 50%. Following mutagenesis reactions and trans-
formation of E. coli, cultures of single colonies were
grown and stored. Six to eight clones from each reaction
were sequenced, and all mutations were detected, and in
different combinations in individual clones. A total of
129 (24 for 4B2A1 Va, 30 for 4B2A1 Vb, 45 for 7A10B2
Va, and 30 for 7A10B2 Vb) colonies were picked and
screened.
For selection, up to five culture aliquots were com-
bined in pools, from which plasmid DNA were isolated.
HEK 293E cells were then transiently transfected (2.4)
with these plasmid preparations such that all possible
combinations of pooled DNA for the a- and b-chains
were tested. Protein production after each transfection
was measured using the hIgG-specific ELISA (2.7), and
wells with increased TCRV-IgC production identified.
Plasmid DNA preparations were then made from the
cultures initially pooled, and these individual DNA
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preparations again combined in a new HEK 293E cell
transfection to finally detect the best pair.
Transfection of HEK 293E cells
HEK 293E cells were transfected using Lipofectamine
2000 transfection reagent from Invitrogen (Carlsbad,
CA) essentially as described [57]. For small scale testing,
cells were seeded in 24 well plates at 2 × 105 cells/well,
and supernatants were tested three days later. For larger
scale protein production, cells were seeded in 750 ml
bottles at 2 × 107 cells/bottle. In these, medium was
harvested and replaced with fresh medium every 2-3
days for three weeks.
Baculovirus production and infection of insect cells
Generation of recombinant baculovira and infection of
Sf9 insect cells was performed using the BaculoGold
Transfection Kit from BD Biosciences (San Diego, CA).
Briefly, samples of pAc vectors with TCR-Ig genes and
baculovirus DNA were co-transfected into Sf9 cells to
generate recombinant baculovira carrying TCR-Ig genes.
After the initial transfection, virus titers were increased
by three repeated Sf9 cell infections.
Protein purification
TCR-Ig fusion proteins were purified from transfected
HEK 293E cell supernatants. Dead cells were removed
by centrifugation, and the supernatant filtered through a
0.45 μm filter and run on a Protein G Sepharose 4 Fast
Flow column from GE Healthcare (Uppsala, Sweden).
Bound protein was eluted with Tris-HCl, pH 2.7, and
the pH in each 1 ml fraction rapidly neutralized with 40
μl Tris-HCl pH 9. Fractions with TCR-Ig (as determined
in ELISA) were concentrated on Amicon Centrifugal Fil-
ter Devices with MWCO 100 000 from Millipore (Biller-
ica, MA). After a 40-70-fold concentration, four rounds
of PBS were added to and spun through the filter col-
umn to replace the elution buffer.
Quantification of TCR-Ig fusion protein
A hIgG3-specific ELISA used to quantify TCR-Ig fusion
protein has been described previously [57]. Briefly, wells
were coated with mouse anti-hIgG3 (clone HP6047), and
TCR-Ig fusion protein added. Biotinylated mouse anti-
hIgG3 (clone HP6050) followed by streptavidin-coupled
alkaline phosphatase (ALP) was used for detection.
TCR-Ig fusion proteins on hIgG1 Fc were quantified
with goat anti-hIgG Fc (1:1000) as coat and ALP-conju-
gated goat anti-hIgG (1:2000) as detection reagent.
TCR-Ig binding to TCR specific antibodies
For TCR-specific ELISAs, wells were coated with 3 μg/
ml anti-TCR Ab (GB113, F23.2, 44-22-1, RR4-7 or H57)
before addition of TCR-Ig fusion proteins. Detection
was with ALP-conjugated goat anti-hIgG (1:5000). All
ELISAs were developed using phosphatase substrate dis-
solved in diethanolamine buffer, pH 9.8. Streptavidin-
ALP was from Amersham Biosciences (Uppsala,
Sweden) whereas phosphatase substrate tablets were
from Sigma-Aldrich.
Flow cytometry
A20 and F9 cells were incubated ON with synthetic
l2315 peptide (amino acid 89-107) from Biopeptide Co
(San Diego, CA) at a final concentration of 50 μM.
Then, additional peptide was added to a final concentra-
tion of 100 μM. After two hours, the cells were stained
with TCR-Ig (at 17 or 100 μg/ml) or control Abs, fol-
lowed by PE conjugated goat anti-hIgG F(ab)2 at 7.5 μg/
ml. Recombinant I-E- and NIP-specific hIgG3 were posi-
tive and negative isotype-matched controls, respectively.
30-50 000 cells were run on a FACSCalibur flow cyt-
ometer from Becton Dickinson (Mountain View, CA)
and analyzed.
Additional material
Additional file 1: Primers for cloning into pAc--Fc.
Additional file 2: Primers for V region mutagenesis.
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